Swiss Re AG
F:SR9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swiss Re AG
F:SR9
|
CH |
|
F
|
Fortress Biotech Inc
F:CNB
|
US |
|
C
|
CRH PLC
XMUN:CRG
|
IE |
|
R
|
Ralph Lauren Corp
DUS:PRL
|
US |
|
Mobvista Inc
F:6MO
|
CN |
|
Sabra Health Care REIT Inc
F:SBC
|
US |
|
Retail Estates NV
F:R6N
|
BE |
|
K
|
Kinross Gold Corp
XMUN:KIN2
|
CA |
|
ANZ Group Holdings Ltd
F:X5Z
|
AU |
|
W
|
Wharf Holdings Ltd
F:WHA
|
HK |
Wall St Price Targets
SR9 Price Targets Summary
Swiss Re AG
According to Wall Street analysts, the average 1-year price target for SR9 is 145.07 EUR with a low forecast of 126.18 EUR and a high forecast of 184.11 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SR9's stock price target?
Price Target
145.07
EUR
According to Wall Street analysts, the average 1-year price target for SR9 is 145.07 EUR with a low forecast of 126.18 EUR and a high forecast of 184.11 EUR.
What is the Revenue forecast for Swiss Re AG?
Projected CAGR
7%
Over the last 14 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 8 years is 7%.
What is the Net Income forecast for Swiss Re AG?
Projected CAGR
6%
Over the last 14 years, the compound annual growth rate for Net Income has been 4%. The projected CAGR for the next 8 years is 6%.
